Treatment effects for which shift or binary analyses are advantageous in acute stroke trials

被引:115
作者
Saver, Jeffrey L. [1 ,2 ]
Gornbein, Jeffrey [3 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Stroke Ctr, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Stat Biomath Consulting Clin, Los Angeles, CA 90095 USA
关键词
MODIFIED RANKIN SCALE; ISCHEMIC-STROKE; THERAPY;
D O I
10.1212/01.wnl.0000341308.73506.b7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: In acute stroke trials, functional outcome may be analyzed by dichotomizing ordinal outcome scales or by evaluating the entire scale range (shift analysis). The conditions under which shift or binary analysis will be more efficient have not been previously well delineated. Methods: Model randomized clinical trials employing the modified Rankin Scale of global handicap were constructed to reflect 1) mild benefits experienced across all ranges of stroke severity (neuroprotective effect), 2) substantial benefits across all ranges of stroke severity (early recanalization effect), 3) substantial benefits across wide range of stroke severity but with limited ability to achieve fully normal outcome (late recanalization effect), 4) benefits clustered at unexpected health state transitions. Results: In neuroprotective models, shift analysis was the most efficient technique in detecting a treatment effect. In the early recanalization models, dichotomization at excellent outcome and shift analysis were of comparable efficiency, both superior to dichotomization at good outcome. In the late recanalization models, dichotomization at good outcome performed best, shift analysis less well, and dichotomization at excellent outcome poorly. In the unexpected benefits model, shift analysis substantially outperformed dichotomization analyses. These patterns held among the seven actual acute trials reporting full range Rankin outcomes and showing treatment benefit identified in the literature. Conclusions: The pattern of treatment effect of the intervention determines whether shift analysis or simple dichotomized analysis will be more efficient. Shift analysis is especially advantageous when treatments confer a relatively uniform, mild benefit to patients over a wide range of stroke severities or confer benefits at unexpected but clinically important health state transitions. Neurology (R) 2009; 72: 1310-1315
引用
收藏
页码:1310 / 1315
页数:6
相关论文
共 18 条
[1]   Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials [J].
Bath, Philip M. W. .
STROKE, 2007, 38 (06) :1911-1915
[2]   Could stroke trials be missing important treatment effects? [J].
Berge, E ;
Barer, D .
CEREBROVASCULAR DISEASES, 2002, 13 (01) :73-75
[3]   Erythropoietin therapy for acute stroke is both safe and beneficial [J].
Ehrenreich, H ;
Hasselblatt, M ;
Dembowski, C ;
Cepek, L ;
Lewczuk, P ;
Stiefel, M ;
Rustenbeck, HH ;
Breiter, N ;
Jacob, S ;
Knerlich, F ;
Bohn, M ;
Poser, W ;
Rüther, E ;
Kochen, M ;
Gefeller, O ;
Gleiter, C ;
Wessel, TC ;
De Ryck, M ;
Itri, L ;
Prange, H ;
Cerami, A ;
Brines, M ;
Sirén, AL .
MOLECULAR MEDICINE, 2002, 8 (08) :495-505
[4]  
FEDEROV V, 2008, CONSEQUENCES DICHOTO
[5]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[6]   Infrared laser therapy for ischemic stroke: A new treatment strategy results of the NeuroThera effectiveness and Safety Trial-1 (NEST-1) [J].
Lampl, Yair ;
Zivin, Justin A. ;
Fisher, Marc ;
Lew, Robert ;
Welin, Lennart ;
Dahlof, Bjorn ;
Borenstein, Peter ;
Andersson, Bjorn ;
Perez, Julio ;
Caparo, Cesar ;
Ilic, Sanja ;
Oron, Uri .
STROKE, 2007, 38 (06) :1843-1849
[7]   NXY-059 for acute ischemic stroke [J].
Lees, KR ;
Zivin, JA ;
Ashwood, T ;
Davalos, A ;
Davis, SM ;
Diener, H ;
Grotta, J ;
Lyden, P ;
Shuaib, A ;
Hårdemark, H ;
Wasiewski, WW .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :588-600
[8]   TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
MARLER, JR ;
BROTT, T ;
BRODERICK, J ;
KOTHARI, R ;
ODONOGHUE, M ;
BARSAN, W ;
TOMSICK, T ;
SPILKER, J ;
MILLER, R ;
SAUERBECK, L ;
JARRELL, J ;
KELLY, J ;
PERKINS, T ;
MCDONALD, T ;
RORICK, M ;
HICKEY, C ;
ARMITAGE, J ;
PERRY, C ;
THALINGER, K ;
RHUDE, R ;
SCHILL, J ;
BECKER, PS ;
HEATH, RS ;
ADAMS, D ;
REED, R ;
KLEI, M ;
HUGHES, S ;
ANTHONY, J ;
BAUDENDISTEL, D ;
ZADICOFF, C ;
RYMER, M ;
BETTINGER, I ;
LAUBINGER, P ;
SCHMERLER, M ;
MEIROSE, G ;
LYDEN, P ;
RAPP, K ;
BABCOCK, T ;
DAUM, P ;
PERSONA, D ;
BRODY, M ;
JACKSON, C ;
LEWIS, S ;
LISS, J ;
MAHDAVI, Z ;
ROTHROCK, J ;
TOM, T ;
ZWEIFLER, R ;
DUNFORD, J ;
ZIVIN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587
[9]   Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke - The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan [J].
Ogawa, Akira ;
Mori, Etsuro ;
Minematsu, Kazuo ;
Taki, Waro ;
Takahashi, Akira ;
Nemoto, Shigeru ;
Miyamoto, Susumu ;
Sasaki, Makoto ;
Inoue, Takashi .
STROKE, 2007, 38 (10) :2633-2639
[10]  
RANKIN J, 1957, Scott Med J, V2, P200